AMR Accelerator

𝗬𝗲𝘀! 𝗪𝗲 𝗖𝗮𝗻 𝗘𝗻𝗱 𝗧𝗕: 𝗖𝗼𝗺𝗺𝗶𝘁, 𝗜𝗻𝘃𝗲𝘀𝘁, 𝗗𝗲𝗹𝗶𝘃𝗲𝗿. This year’s World Health Organization theme is a strong call for optimism, action and responsibility, and we at AMR Accelearator are inspired! Join us for our next webinar with health economics experts to examine TB's global cost burden on health systems and patients. 𝗪𝗲 𝘄𝗶𝗹𝗹 𝗰𝗼𝘃𝗲𝗿: ✔️The range of costs associated with TB ✔️How we measure these ✔️Role of health economics into the priorities for new TB treatment development. 𝗔 𝗠𝘂𝘀𝘁-𝗔𝘁𝘁𝗲𝗻𝗱 𝗳𝗼𝗿: 🔬 People working in TB or antimicrobial drug development. 📉 Individuals interested in the health economics of TB, including health technology assessment agencies. 🌟 Anyone enthusiastic about advancing the field. Hosted by ERA4TB and COMBINE, this is a first of 3-part webinar series focused on health economics and TB. 👉 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗻𝗼𝘄 𝗮𝘁 https://lnkd.in/dcW_6fKj Follow us along to explore more in detail about the critical issues surrounding TB! #AMR #webinar #TB #Healtheconomics Innovative Health Initiative (IHI)

𝗔𝗿𝗲 𝗪𝗲 𝗢𝘃𝗲𝗿𝗹𝗼𝗼𝗸𝗶𝗻𝗴 𝗞𝗲𝘆 𝗙𝗮𝗰𝘁𝗼𝗿𝘀 𝗶𝗻 𝗛𝗙𝗦-𝗧𝗕 𝗘𝘅𝗽𝗲𝗿𝗶𝗺𝗲𝗻𝘁𝘀? In this week’s edition we present: “𝗘𝘃𝗮𝗹𝘂𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗰𝗿𝗶𝘁𝗶𝗰𝗮𝗹 𝗽𝗮𝗿𝗮𝗺𝗲𝘁𝗲𝗿𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗵𝗼𝗹𝗹𝗼𝘄-𝗳𝗶𝗯𝗿𝗲 𝘀𝘆𝘀𝘁𝗲𝗺 𝗳𝗼𝗿 𝘁𝘂𝗯𝗲𝗿𝗰𝘂𝗹𝗼𝘀𝗶𝘀: 𝗔 𝗰𝗮𝘀𝗲 𝘀𝘁𝘂𝗱𝘆 𝗼𝗳 𝗺𝗼𝘅𝗶𝗳𝗹𝗼𝘅𝗮𝗰𝗶𝗻”, by Aguilar-Ayala DA et al., 2024. In this paper, our researchers talk about the critical parameters that are overlooked in the Hollow Fiber System for Tuberculosis (HFS-TB) experiments and their impact on experimental conclusions. 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: ✅ The need to test drug interactions with the fibers before running actual HFS-TB assays. ✅ How the way samples are collected may influence results. ✅ The importance of the period before drug infusion in affecting experimental outcomes. 👉 Read the complete paper at https://lnkd.in/eCkN-uvg 👉 For more information visit https://lnkd.in/dgJedi8K. #publications #TB #EndTB #WorldTBDay

📢 UNITE4TB is pleased to announce that the ENABLE study is the latest trial to be added to its growing clinical trial program, marking another step forward in the fight against tuberculosis (TB) 💪 By integrating ENABLE, we are strengthening our commitment to accelerating the development of safer, more effective TB treatments. The study is being conducted under the collaboration between BioVersys AG and GSK, with clinical trial implementation led by TASK. 🔗 Read more 👉 https://lnkd.in/ewM2unXS #UNITE4TB #TBResearch #ClinicalTrials #GlobalHealth #YesWeCanEndTB #CommitInvestDeliver #PublicPrivatePartnership funded by the Innovative Medicines Initiative 2 (Innovative Health Initiative (IHI)). AMR Accelerator

Our colleagues from Universidad de Zaragoza were on TV this morning for #WorldTBday2025 talking about the brilliant work they have been doing within TB research, both within and outside of ERA4TB! Ainhoa Lucía Quintana discussed the research being done at the University of Zaragoza, including their role in leading the ERA4TB In Vitro work package and the implementation of the drug evaluation tool, the hollow fibre system. Cristina Villellas Arilla described plans for the public plenary sessions at the ERA4TB General Assembly in May, and the work Universidad Carlos III de Madrid and other Spanish partners are doing integrating AI and clinical trials. Finally, Santiago R. spoke about a recent publication on a new compound for TB, Sanfetrinem #WorldTBday #TBresearch

𝗨𝗻𝗶𝘁𝗲 𝘁𝗼 𝗘𝗻𝗱 𝗧𝘂𝗯𝗲𝗿𝗰𝘂𝗹𝗼𝘀𝗶𝘀: 𝗔 𝗖𝗮𝗹𝗹 𝗳𝗼𝗿 𝗔𝗰𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗛𝗼𝗽𝗲 This World TB Day, we reaffirm our commitment to combating tuberculosis through innovation, collaboration and action. Our projects are making a real impact and expanding access to early diagnosis, improving treatment outcomes and driving research for better solutions. Innovative Health Initiative (IHI) ERA4TB UNITE4TB RespiriTB BioVersys AG #WorldTBDay #worldtbday2025 #YesWeCanEndTB #EndTB #WHO

𝗔𝗻𝗼𝘁𝗵𝗲𝗿 𝗠𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲 𝗳𝗼𝗿 ERA4TB 𝗖𝗼𝗻𝘀𝗼𝗿𝘁𝗶𝘂𝗺! 🎉 New research paper published on implementing best practices on data generation and reporting of Mycobacterium tuberculosis 𝘪𝘯-𝘷𝘪𝘵𝘳𝘰 assays. 𝗔𝗰𝗰𝗲𝘀𝘀 𝘁𝗵𝗲 𝗣𝗮𝗽𝗲𝗿 📜 For those interested in exploring the full research, it is available here: 🔗 https://lnkd.in/g5-ViTNq This publication represents another step towards understanding how the collaboration between partners in an IMI consortium can be further harmonized to implement and standardize experimental protocols and data management for consistent reporting and sharing within the AMR Accelerator program. 👉 𝗝𝗼𝗶𝗻 𝘁𝗵𝗲 𝗰𝗲𝗹𝗲𝗯𝗿𝗮𝘁𝗶𝗼𝗻 𝘄𝗶𝘁𝗵 𝘆𝗼𝘂𝗿 𝗹𝗼𝘃𝗲 & 𝘀𝘂𝗽𝗽𝗼𝗿𝘁! 𝗟𝗶𝗸𝗲 𝗮𝗻𝗱 𝘀𝗵𝗮𝗿𝗲 𝘄𝗶𝘁𝗵 𝘁𝗵𝗼𝘀𝗲 𝘄𝗵𝗼 𝗺𝗮𝘆 𝗳𝗶𝗻𝗱 𝗶𝘁 𝗺𝗲𝗮𝗻𝗶𝗻𝗴𝗳𝘂𝗹! #AMR #EndTB #MedicalResearch #HealthcareInnovation Innovative Health Initiative (IHI) ERA4TB RespiriNTM RespiriTB BioVersys AG UNITE4TB

As part of International Women’s Day, we asked consortium members from across the ERA4TB workstreams to tell us why they feel it is important for women to be involved in TB research. We also asked them what they would like to see happen in the world to #AccelerateAction – on advancing and celebrating women’s equality worldwide. You can read here some of the highlights of what they told us, and over the next few days, we will be sharing the longer interviews so you can find out more. Gilla Kaplan one of our Scientific Advisory Board members gave the following advice to women scientists: “If you go into TB research, success will clearly require hard work, technical skill and a talent to overcome all the potential difficulties encountered along the research path. However, impact on the epidemic will require being part of a research team that has the capacity to remain focused and work together to deliver on the goals undertaken. Be the passionate and collaborative researcher you know it will take to help TB patients and the communities they are part of.” A big thank you to everyone who took part in the campaign! Anna Upton, Deborah Recchia, Ainhoa Lucía Quintana, Lara V., Christine Roubert, Hala Mansour, Evotec, Università di Pavia, Institut Pasteur de Lille, Charles III University of Madrid, Universidad de Zaragoza, GSK, Institut Pasteur, AMR Accelerator, Innovative Health Initiative (IHI), SYNAPSE Research Management Partners #IWD #AccelerateAction #TBResearch

First time in many years an increase had been reported in the number of people affected with TB, among which 450 000 new cases of rifampicin-resistant TB were confirmed between 2020-21. ⚠️ 𝗜𝘀𝘀𝘂𝗲𝘀 𝘄𝗶𝘁𝗵 𝗰𝘂𝗿𝗿𝗲𝗻𝘁 𝗿𝗲𝗴𝗶𝗺𝗲𝗻𝘀 𝗳𝗼𝗿 𝗗𝗥-𝗧𝗕 ? - length of treatment - significant side effects - emergence of drug resistance - drug–drug interactions 💫 𝗕𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵𝘀? 𝗔𝗹𝗽𝗶𝗯𝗲𝗰𝘁𝗶𝗿 (𝗕𝗩𝗟-𝗚𝗦𝗞𝟬𝟵𝟴) is the first small molecule in clinical development targeting mycobacterial transcription regulation. Alpibectir enhances the bioactivation of ethionamide (Eto) allowing for lower doses with fewer side effects, potentially transforming TB treatment. In this week’s edition we present: “𝗙𝗶𝗿𝘀𝘁-𝗶𝗻-𝗵𝘂𝗺𝗮𝗻 𝘀𝘁𝘂𝗱𝘆 𝗼𝗳 𝗮𝗹𝗽𝗶𝗯𝗲𝗰𝘁𝗶𝗿 (𝗕𝗩𝗟-𝗚𝗦𝗞𝟬𝟵𝟴), 𝗮 𝗻𝗼𝘃𝗲𝗹 𝗽𝗼𝘁𝗲𝗻𝘁 𝗮𝗻𝘁𝗶-𝗧𝗕 𝗱𝗿𝘂𝗴” by Pieren et al., 2024 under TRIC-TB. 🧪 𝗠𝗮𝗷𝗼𝗿 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 ? - Reduces drug resistance concerns - Improves patient adherence with lower toxicity - Maximizes the potential of a 60-year-old drug 👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗮𝗽𝗲𝗿: https://lnkd.in/dWdGqaQn What are your thoughts on the future of TB treatment? Let's discuss in comments! #TB #Innovation #DrugResistance #AMR

The #PrIMAVeRa_AMR consortium celebrates the acceptance of its newly produced video 📽️ to be presented at #ESCMIDGlobal Event 2025 in Vienna! This video gives an accessible introduction to the project’s goals and methods, and includes interviews with key partners including: -       Dr. Irina Meln, PhD, Project Coordinator, of the European Vaccine Initiative (EVI) Vaccine Initiative -       Dr. Marc Bonten, Scientific Lead, of the UMC Utrecht -       Dr. Venanzio Vella, EFPIA - European Federation of Pharmaceutical Industries and Associations Lead, of GSK Vaccines 📝Read more, and view the video here: https://lnkd.in/dn5DJaGb By lowering the occurrence of infectious diseases, reducing the reliance on #antibiotics, and limiting the development of #AMR within communities, #vaccines can serve as a crucial tool in combating and managing AMR, and ultimately #savelives. --- #Eufunded #StopSuperbugs #StopSuperbugs Innovative Health Initiative (IHI), AMR Accelerator  ESCMID - European Society of Clinical Microbiology and Infectious Diseases

Last month, we took a deep dive into how our researchers developed a ML model which can help identify new antimicrobial compounds. Check out the key takeaways & watch the recording of our researchers as they discuss how the model was developed and its application to combat AMR.     👉 Watch here: https://lnkd.in/e8irM6FR 👉 Visit our website to learn more: https://lnkd.in/e8irM6FR Let us know in comments what was your biggest takeaway from our last month discussion around AI-based models in tackling AMR. #AMR #webinar #recording #ML Innovative Health Initiative (IHI) ERA4TB RespiriNTM RespiriTB UNITE4TB Lygature